Provided by Tiger Trade Technology Pte. Ltd.

iShares Genomics Immunology and Healthcare ETF

38.59
-0.1515-0.39%
Post-market: 38.590.00000.00%16:10 EDT
Volume:73.82K
Turnover:2.84M
Market Cap:260.47M
PE:- -
High:38.65
Open:38.65
Low:38.17
Close:38.74
52wk High:41.49
52wk Low:22.33
Shares:6.75M
Float Shares:6.75M
Volume Ratio:0.40
T/O Rate:1.09%
Dividend:0.28
Dividend Rate:0.73%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Revolution Medicines Set to Post 'Strong Launch' for Rasonque, UBS Says

MT Newswires Live
·
Aug 29

mRNA immunotherapy discontinuation a negative for BioNTech, says Morgan Stanley

TIPRANKS
·
Aug 28

Moderna Stock Falls on $2B Notes Deal: Is the Cancer Rally Still Intact?

TradingKey
·
Aug 28

Argus Research Upgrades Moderna to Buy From Hold, $180 Price Target

MT Newswires Live
·
Aug 28

Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs

GlobeNewswire
·
Aug 28

Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes

Reuters
·
Aug 28

Moderna Price Target Announced at $180.00/Share by Argus Research

Dow Jones
·
Aug 28

U.S. Stocks on the MOVE-Cytokinetics, Moderna, Ulta Beauty

Reuters
·
Aug 28

Success After a Century of Failures: Inside Moderna and Merck's Cancer Vaccine Breakthrough

Reuters
·
Aug 28

Moderna Prices $2.6 Billion Convertible Notes due 2032

MT Newswires Live
·
Aug 28

Moderna Rises After Upsized $2.6 Bln Convertible Bond Sale

Reuters
·
Aug 28

Incyte Partner Knight Seeks Supplemental Approval for Minjuvi Combination in Brazil

MT Newswires Live
·
Aug 28

US Regulator Approves Novel Pancreatic Cancer Therapy, Marking Major Win for Independent Biotech

Deep News
·
Aug 28

Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent

Dow Jones
·
Aug 28

FDA Approves Seasonal Covid-19 Vaccines from Moderna, Pfizer, BioNTech

Dow Jones
·
Aug 28

Moderna Inc. Stock Slips 4.6%, Underperforms Peers

Dow Jones
·
Aug 28

Twist Bioscience CEO Emily Leproust Sells USD 6.28 Million in Common Shares

Reuters
·
Aug 28

Moderna Wins FDA Approval for Updated 2026-2027 COVID-19 Vaccines Targeting JN.1-Lineage XFG Subvariant

Reuters
·
Aug 28

Moderna - FDA Approved Sbla for 2026-2027 Formulas for Spikevax and Mnexspike

THOMSON REUTERS
·
Aug 28

Moderna - Updated Formula for Spikevax is NOW Approved for Individuals 6 Months Through 64 Years of Age with at Least One Underlying Condition

THOMSON REUTERS
·
Aug 28